Cargando…

The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review

Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence will occur in approximately 20%-35% of people initially affected, with 40%-60% of these having a second re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thandavaram, Abhay, Channar, Aneeta, Purohit, Ansh, Shrestha, Bijay, Patel, Deepkumar, Shah, Hriday, Hanna, Kerollos, Kaur, Harkirat, Alazzeh, Mohammad S, Mohammed, Lubna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468512/ https://www.ncbi.nlm.nih.gov/pubmed/36120235 http://dx.doi.org/10.7759/cureus.27979

Ejemplares similares

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review
por: Hanna, Kerollos S, et al.
Publicado: (2022)

Increased Threat of Thyroid Diseases in Patients With Sjogren’s Syndrome: A Systematic Review
por: Kaur, Harkirat, et al.
Publicado: (2022)

The Outcome of Electrical Cardioversion in Hyperthyroid Induced Atrial Fibrillation
por: Shah, Hriday, et al.
Publicado: (2023)

The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review
por: Shrestha, Bijay, et al.
Publicado: (2022)

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient
por: Fein, Aaron, et al.
Publicado: (2022)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
por: Navalkele, Bhagyashri D, et al.
Publicado: (2018)

Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
por: Shen, Judong, et al.
Publicado: (2020)

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
por: Alonso, Carolyn D, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
por: Askar, Sally, et al.
Publicado: (2018)

Antibiotics Associated With Clostridium difficile Infection
por: Rafey, Abdur, et al.
Publicado: (2023)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection
por: Džunková, Mária, et al.
Publicado: (2016)

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
por: Prabhu, Vimalanand S, et al.
Publicado: (2017)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
por: Shaw, Peter, et al.
Publicado: (2017)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland
por: Oksi, Jarmo, et al.
Publicado: (2019)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

Ischemic Colitis Is a Risk Factor for Clostridium difficile Infection
por: Khazaaleh, Shrouq, et al.
Publicado: (2022)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
por: Mileto, Steven J., et al.
Publicado: (2022)

Appendectomy as a Potential Predisposing Factor for the Development of Recurrent and Fulminant Clostridium Difficile
por: Heindl, Stacey E, et al.
Publicado: (2020)

Fecal Microbiota Transplant in Recurrent Clostridium Difficile Infections: A Systematic Review
por: Gupta, Kunal, et al.
Publicado: (2022)

Risk Factors Associated With Clostridium difficile-Associated Diarrhea
por: Gupta, Aarzoo, et al.
Publicado: (2021)

Bezlotoxumab in Patients with a Primary Clostridioides difficile Infection: A Literature Review
por: Granata, Guido, et al.
Publicado: (2022)

Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods?
por: Lin, Zayar, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
por: Salavert, Miguel, et al.
Publicado: (2018)

Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2020)

An Unusual Presentation of Severe Sepsis Due to Clostridium difficile Enteritis
por: Abid, Haisam, et al.
Publicado: (2019)

The Impact of Appendectomy in Clostridium difficile Infection and Length of Hospital Stay
por: Essrani, Rajesh, et al.
Publicado: (2020)

Atypical Hemolytic Uremic Syndrome Associated With Clostridium Difficile Infection
por: Khurshid, Qasim, et al.
Publicado: (2020)

Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection
por: Waqas, Muhammad, et al.
Publicado: (2022)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Probiotics and Clostridium Difficile: A Review of Dysbiosis and the Rehabilitation of Gut Microbiota
por: Kalakuntla, Ashish S, et al.
Publicado: (2019)

Clostridium Difficile and Noncirrhotic Hyperammonnemia in a Patient With COVID-19 Infection
por: Ramalingam, Sathishkumar, et al.
Publicado: (2021)

1496. Bezlotoxumab Administered at the End of a Suppressive Drug Regimen for Patients with Multiply Recurrent Clostridioides difficile Infection
por: Tan, Xing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4524t92u9uk242iihqf9iudnl4